Cutler Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Cutler Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$1K	–	4069
2022 Q4	$1K	Buy	+400	New	+$6.18K	﹤0.01%	3996

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's FDMT Position: Q1 2024 in Review

Cutler Group sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 1,000 shares — an estimated $25.5K sold.

Cutler Group first reported a position in FDMT in Q1 2023 and held it in 4 quarters. The position peaked at $20K in Q4 2023. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

Cutler Group reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 1,000 4D Molecular Therapeutics shares in Q1 2024, an estimated $25.5K.
Cutler Group first reported a position in 4D Molecular Therapeutics in Q1 2023 and held it in 4 quarters.
Cutler Group's 4D Molecular Therapeutics position peaked at $20K in Q4 2023.
147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.